- First Patient Cured of Sickle Cell Anemia
- FDA Warns of Rising Injuries From Misuse of Laughing Gas
- 1 in 3 Children Now Suffer From Chronic Illness
- No Link Between COVID Vaccine During Pregnancy And Birth Defects, Study Says
- Death Risk Higher Among People With Arthritis And COPD
- Depression, Anxiety Common Among Chronic Pain Patients
- Steep Decline In Fertility Among U.S. Women Younger Than 30
- Time Of Day, Year Matters For Asthma Testing
- Early Detection of Colon Cancer Is Critical for Women
- Scientists Develop Rapid Bird Flu Detector for Airborne Test
Raplixa Approved to Control Surgical Bleeding

Raplixa (human fibrin sealant) has been approved by the U.S. Food and Drug Administration to help control bleeding during surgery, the agency said in a news release.
Raplixa’s use is sanctioned when standard surgical techniques — including sutures — are “ineffective or impractical,” the FDA said. The spray-dried product is dissolved in the blood and triggers a reaction that promotes clotting to help stop bleeding.
The product contains fibrinogen and thrombin, two proteins derived from human plasma. Its manufacturing process includes purification designed to render blood-borne viruses inactive, the agency said.
Raplixa, designed to be used with an absorbable gelatin sponge, was clinically evaluated among more than 700 people over 11 months. The most common side effects included surgical pain, nausea, constipation, fever and lower blood pressure.
The product is manufactured by ProFibrix BV, a unit of The Medicines Company, based in Parsippany, N.J.
More information
Visit the FDA to learn more.
Source: HealthDay
Copyright © 2025 HealthDay. All rights reserved.